WALTHAM, Mass.– BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced that two abstracts have been accepted for poster presentation at the United States and Canadian Academy of Pathology (USCAP) 114th Annual Meeting. The event, held from March 22-27 at the Boston Convention and Exhibition Center in Boston, MA, is the premier gathering of pathology and laboratory medicine professionals, showcasing cutting-edge research, diagnostic advancements and emerging technologies to advance patient care and precision medicine.
A recent pilot study uncovered associations between bacterial profiles, the tumor microenvironment (TME), and histology in metastatic castration-resistance prostate cancer (mCRPC). Using BostonGene’s machine learning-based tools, RNA sequencing data were analyzed to characterize each sample’s microbiota and TME. Distinct bacterial patterns were present across prostate cancer subtypes and TME classifications, with strong correlations observed among the microbiomes of metastatic sites.
This collaborative study identified novel GBM TIME subtypes associated with prognosis. Unsupervised clustering was applied to transcriptomic data from a meta-cohort of 867 publicly available samples and 30 BostonGene Tumor PortraitTM test samples to define five TIME subtypes linked with overall survival. This study illustrates the power of molecular profiling for identifying prognostic biomarkers in GBM.
